Exchange: NASDAQ·Updated 05:23 PM EDT

IRWD News

News
all
press releases
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET. A live webcast of Ironwoods fireside chat will be accessible through the Investors...
Business Wire
More News
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.
Zacks
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of +19.23% and -5.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing lifechanging therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance. Throughout the first half of...
Business Wire
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S.) or (646...
Business Wire
Community Health Q2 Loss Wider Than Expected, 2026 View Lowered
CYH posts a wider-than-expected Q2 loss as revenues fall and the company cuts its 2026 revenue, EBITDA and earnings outlook.
Zacks
UnitedHealth Tops Q2 Earnings on Cost Control, Raises '26 Outlook
UNH beats Q2 earnings estimates on lower medical costs and stronger Optum Insight, then raises its 2026 EPS and cash flow outlook.
Zacks
Here's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Ironwood Pharmaceuticals Names Jeffrey Silber Chief Medical Officer
(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD) announced the retirement of Chief Medical Officer and Head of Research and Drug Development Michael Shetzline and the appointment of Jeffrey Silber as his successor. Silber will oversee Research and Drug Development, Regulatory A...
Nasdaq News: Markets
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing lifechanging therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael...
Business Wire

Advertisement|Remove ads.